BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)March 25, 2026
Share Facebook Twitter LinkedIn Pinterest Email Gaza ceasefire talks resume between U.S., Hamas – report
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)March 25, 2026
Absci outlines $25B annual market potential for ABS-201 in AGA and advances endometriosis clinical program (NASDAQ:ABSI)March 25, 2026
